AR093843A1 - Derivados de piridina agonistas de receptores cb2 - Google Patents

Derivados de piridina agonistas de receptores cb2

Info

Publication number
AR093843A1
AR093843A1 ARP130104545A ARP130104545A AR093843A1 AR 093843 A1 AR093843 A1 AR 093843A1 AR P130104545 A ARP130104545 A AR P130104545A AR P130104545 A ARP130104545 A AR P130104545A AR 093843 A1 AR093843 A1 AR 093843A1
Authority
AR
Argentina
Prior art keywords
dioxo
oxo
cycloalkyl
alkyl
phenylalkyl
Prior art date
Application number
ARP130104545A
Other languages
English (en)
Spanish (es)
Inventor
Frei Beat
Gobbi Luca
Grether Uwe
Kimbara Atsushi
Nettekoven Matthias
Rogers-Evans Mark
Schulz-Gasch Tanja
Roever Stephan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR093843A1 publication Critical patent/AR093843A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ARP130104545A 2012-12-07 2013-12-06 Derivados de piridina agonistas de receptores cb2 AR093843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07

Publications (1)

Publication Number Publication Date
AR093843A1 true AR093843A1 (es) 2015-06-24

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104545A AR093843A1 (es) 2012-12-07 2013-12-06 Derivados de piridina agonistas de receptores cb2

Country Status (33)

Country Link
US (1) US9522886B2 (enExample)
EP (2) EP2928881B1 (enExample)
JP (1) JP6426618B2 (enExample)
KR (1) KR20150092282A (enExample)
CN (2) CN104837831B (enExample)
AR (1) AR093843A1 (enExample)
AU (2) AU2013354278B2 (enExample)
BR (1) BR112015012919A2 (enExample)
CA (1) CA2890100A1 (enExample)
CL (1) CL2015001536A1 (enExample)
CO (1) CO7350620A2 (enExample)
CR (1) CR20150250A (enExample)
DK (1) DK2928881T3 (enExample)
EA (1) EA026669B1 (enExample)
ES (1) ES2668690T3 (enExample)
HR (1) HRP20180672T1 (enExample)
HU (1) HUE036911T2 (enExample)
IL (1) IL239075B (enExample)
LT (1) LT2928881T (enExample)
MA (1) MA38239A1 (enExample)
MX (1) MX2015007155A (enExample)
NO (1) NO2928881T3 (enExample)
PE (1) PE20151025A1 (enExample)
PH (1) PH12015501083A1 (enExample)
PL (1) PL2928881T3 (enExample)
PT (1) PT2928881T (enExample)
RS (1) RS57143B1 (enExample)
SG (2) SG10201800170YA (enExample)
SI (1) SI2928881T1 (enExample)
TW (1) TWI600645B (enExample)
UA (1) UA114656C2 (enExample)
WO (1) WO2014086705A1 (enExample)
ZA (1) ZA201503969B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102217297B1 (ko) 2013-03-07 2021-02-22 에프. 호프만-라 로슈 아게 신규 피라졸 유도체
BR112015024272A2 (pt) 2013-03-26 2017-07-18 Hoffmann La Roche novos derivados de piridina
TR201809417T4 (tr) 2013-05-02 2018-07-23 Hoffmann La Roche Cb2 reseptör agonistleri olarak purin türevleri.
PE20160039A1 (es) 2013-05-02 2016-01-28 Hoffmann La Roche NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA
SI3041843T1 (sl) 2013-09-06 2019-04-30 F. Hoffmann-La Roche Ag Derivati triazolo(4,5-d)pirimidina kot antagonisti receptorja CB2
WO2015150438A1 (en) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
UA122591C2 (uk) * 2015-12-09 2020-12-10 Ф. Хоффманн-Ля Рош Аг Фенільні похідні як агоністи канабіноїдного рецептора 2
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
CN110753690B (zh) 2017-06-20 2023-12-05 豪夫迈·罗氏有限公司 吡啶衍生物
WO2019201718A1 (en) * 2018-04-18 2019-10-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
WO2020002280A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020002270A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
AU2019294256B2 (en) 2018-06-27 2024-06-20 Eth Zuerich Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
CN114502538A (zh) * 2019-09-30 2022-05-13 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2022225832A1 (en) * 2021-04-19 2022-10-27 Chemocentryx, Inc. Azetidinyl-acetamides as cxcr7 inhibitors
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008040649A2 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
LT2928881T (lt) 2018-06-11
JP6426618B2 (ja) 2018-11-21
NO2928881T3 (enExample) 2018-08-11
EP2928881B1 (en) 2018-03-14
US9522886B2 (en) 2016-12-20
CN104837831B (zh) 2017-10-31
TWI600645B (zh) 2017-10-01
DK2928881T3 (en) 2018-05-28
SI2928881T1 (en) 2018-07-31
CL2015001536A1 (es) 2015-10-23
EP2928881A1 (en) 2015-10-14
IL239075A0 (en) 2015-07-30
HUE036911T2 (hu) 2018-08-28
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
UA114656C2 (uk) 2017-07-10
CN104837831A (zh) 2015-08-12
EA026669B1 (ru) 2017-05-31
MA38239A1 (fr) 2017-03-31
SG11201504416XA (en) 2015-07-30
EP3357918A1 (en) 2018-08-08
JP2016501240A (ja) 2016-01-18
RS57143B1 (sr) 2018-07-31
IL239075B (en) 2018-11-29
PH12015501083B1 (en) 2015-08-03
PL2928881T3 (pl) 2018-07-31
BR112015012919A2 (pt) 2017-07-11
HK1208031A1 (en) 2016-02-19
CO7350620A2 (es) 2015-08-10
ES2668690T3 (es) 2018-05-21
US20150307452A1 (en) 2015-10-29
HRP20180672T1 (hr) 2018-06-01
MX2015007155A (es) 2015-10-14
AU2017279648A1 (en) 2018-01-18
WO2014086705A1 (en) 2014-06-12
PH12015501083A1 (en) 2015-08-03
AU2013354278A1 (en) 2015-05-14
TW201427951A (zh) 2014-07-16
CA2890100A1 (en) 2014-06-12
AU2013354278B2 (en) 2017-10-12
KR20150092282A (ko) 2015-08-12
SG10201800170YA (en) 2018-02-27
CN107674061A (zh) 2018-02-09
ZA201503969B (en) 2016-04-28
EA201591064A1 (ru) 2015-09-30
CR20150250A (es) 2015-06-11

Similar Documents

Publication Publication Date Title
AR093843A1 (es) Derivados de piridina agonistas de receptores cb2
AR095721A1 (es) Derivados de piridina
AR093805A1 (es) Derivados de piridina agonistas del receptor 2 de cannabinoides
AR093806A1 (es) Derivados de piridina agonistas de receptores cb2
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR088969A1 (es) Derivados de pirrolidina
AR102539A1 (es) Triazolo[4,5-d]pirimidinas
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
AR091781A1 (es) Antagonistas del receptor de 5-ht3
PE20171789A1 (es) Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR070268A1 (es) Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende
WO2014117076A8 (en) Alkyl aromatic hydroalkylation for the production of plasticizers
AR076922A1 (es) Benzodiazepinas como inhibidores de pi3k/mtor, una composicion farmaceutica que las comprende, metodos para su fabricacion y su uso en el tratamiento del cancer.
AR064635A1 (es) Derivados de benzotiazolona
AR076666A1 (es) Derivados azabiciclicos como inhibidor de hsl (lipasa sensible a las hormonas)
AR090966A1 (es) Picolinamidas macrociclicas como fungicidas
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
AR093804A1 (es) Derivados de pirazina agonistas de receptores cb2
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
PE20081791A1 (es) Dos derivados ciclicos de oxomorfolina

Legal Events

Date Code Title Description
FB Suspension of granting procedure